GV20 Therapeutics

GV20 Therapeutics is an innovative drug company with unique technology in the discovery of new targets for cancer immunotherapy and the development of antibody drugs. Relying on the advanced CRISPR whole-genome screening technology from Professor Xiaole Shirley Liu’s laboratory at Harvard University in the United States, GV20 Therapeutics possesses a guide RNA (gRNA) library covering the entire genome as well as customized libraries (such as drug target gene libraries), enabling the screening of essential genes under specific cell types and different treatment conditions. The company applies CRISPR whole-genome screening to discover new targets, biomarkers, and construct novel combination therapies. By utilizing innovative genomics and artificial intelligence technologies, GV20 Therapeutics accelerates the research and development of new cancer drugs. Over the past few years, GV20 Therapeutics has built its proprietary gene screening and functional genomics platforms to identify new drug targets for cancer. Based on these two core technology platforms, GV20 Therapeutics’ first original antibody drug targets a novel immune checkpoint in cancer. Preclinical study results show that this antibody is not only effective as a monotherapy but also demonstrates significant efficacy when combined with existing immunotherapy drugs.